MK-4716

MK-4716 is an investigational oral small-molecule anticancer agent being developed by Merck for the treatment of advanced solid tumors, including KRAS‑altered malignancies. In a first‑in‑human phase 1 study, MK-4716 is administered as monotherapy and in combination with the anti‑PD‑1 antibody pembrolizumab or the anti‑EGFR antibody cetuximab in participants with locally advanced unresectable or metastatic solid tumors, as well as metastatic non‑small cell lung cancer with KRAS alterations.[1][3][8][9] Pharmacokinetic endpoints in this trial (AUC, Cmax, Ctrough, and half‑life) indicate that MK‑4716 is being characterized as a systemic, orally available targeted therapy, although its precise molecular target and mechanism of action have not yet been publicly disclosed.[1][8]